News Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 15:49:13 17/02/2026 GMT			5-day change	1st Jan Change
23.88 ^EUR	+2.25%		+1.06%	-7.23%

02-11	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region	MT
02-11	Swiss stocks - Factors to watch on February 11	RE

All News

02-11	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region	MT
02-11	Swiss stocks - Factors to watch on February 11	RE
02-11	Formycon : Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region	PU
02-11	Formycon says Lotus Pharmaceutical to commercialize its Keytruda biosimilar in Asia-Pacific	RE
02-11	Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region	EQ
01-14	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
01-13	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
01-13	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
12-24	Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)	AQ
12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE
12-23	FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner	EQ
12-23	Formycon AG and Bioeq AG Announce the U.S. Food and Drug Administration Approves Nufymco®?	CI
12-22	INDEX MONITOR: Numerous Changes in MDax and SDax - Dax Remains Unchanged	DP
12-18	Formycon AG(XTRA:FYB) dropped from Germany SDAX (Total Return) Index	CI
12-09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
12-09	Formycon AG and Zydus Lifesciences Limited Partner for Exclusive Licensing and Supply Agreement of FYB206, a Biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	CI
12-09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206	RE
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	AQ
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	EQ
12-09	Formycon Ag and Zydus Lifesciences Limited Enter into Strategic Partnership for the Exclusive Licensing and Supply of Checkpoint Inhibitor Fyb206	CI
12-04	Formycon AG and MS Pharma Sign Exclusive Commercialization Partnership for Keytruda®? Biosimilar Candidate FYB206 for the MENA Region	CI
12-04	Formycon Secures First Marketing Partnership for Keytruda Biosimilar	DP
12-04	Formycon, MS Pharma Enter Licensing Deal for Keytruda Biosimilar in MENA	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

All News

Filters